Company GenSight Biologics S.A.

Equities

SIGHT

FR0013183985

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for GenSight Biologics S.A.

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Euronext Paris Other stock markets 11:21:43 2024-04-24 am EDT			5-day change	1st Jan Change
0.414 ^EUR	+1.72%		-1.90%	-10.00%

Apr. 05	GenSight: financial visibility assured until the end of April	CF
Mar. 25	GenSight: share price falls, limited financial visibility	CF

GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives.

At the end of 2023, the company had a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).

Number of employees: 16

EUR in Million	2022	Weight	2023	Weight	Delta
Novel Therapies for Mitochondrial and Neurodegenerative Disease 100.0 %	3	100.0 %	1	100.0 %	-50.93%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	3	100.0 %	1	100.0 %	-50.93%

Managers	Title	Age	Since
Laurence Rodriguez CEO	Chief Executive Officer	56	21-05-18
Scott Jeffers CTO	Chief Tech/Sci/R&D Officer	-	22-03-31
Magali Taiel CTO	Chief Tech/Sci/R&D Officer	-	18-08-31
Sissel Rodahl PRN	Corporate Officer/Principal	-	22-01-30
Marion Ghibaudo PRN	Corporate Officer/Principal	-	21-06-09
Julio Benedicto SAM	Sales & Marketing	-	17-10-31

Members of the board	Title	Age	Since
Michael Wyzga CHM	Chairman	69	13-09-30
José-Alain Sahel FOU	Founder	68	11-12-31
Cédric Moreau BRD	Director/Board Member	37	19-06-10
Maritza McIntyre BRD	Director/Board Member	58	19-06-10
Françoise de Craecker BRD	Director/Board Member	62	21-05-15
Simone Seiter BRD	Director/Board Member	57	17-04-18
Elsy Boglioli Hofman BRD	Director/Board Member	42	20-09-30
Laurence Rodriguez CEO	Chief Executive Officer	56	21-05-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,309,073	42,060,695 ( 64.40 %)	262,100 ( 0.4013 %)	64.40 %

Name	Equities	%	Valuation
Amiral Gestion SA 0.9339 %	731,910	0.9339 %	317 766 €
Argenta Spaarbank NV 0.4477 %	350,875	0.4477 %	152 336 €
Montpensier Finance SAS 0.0805 %	63,084	0.0805 %	27 389 €
MW Gestion SA 0.0552 %	43,250	0.0552 %	18 777 €
FINEXIS SA 0.0447 %	35,000	0.0447 %	15 196 €
Lyxor International Asset Management SAS 0.0397 %	31,082	0.0397 %	13 495 €
Financière Arbevel SA 0.0212 %	16,586	0.0212 %	7 201 €
Qrenta Agencia de Valores SA 0.0166 %	12,999	0.0166 %	5 644 €
ACA Asset Management Company & Associés SASU 0.0154 %	12,030	0.0154 %	5 223 €

Gensight Biologics SA

74, rue du Faubourg Saint-Antoine

75012, Paris

+33 1 76 21 72 20

http://www.gensight-biologics.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.414 EUR

Average target price

0.4 EUR

Spread / Average Target

-3.38%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GENSIGHT BIOLOGICS S.A.	-10.00%	34.52M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs